Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial

Authors

Ian M. Catlett (ORCID: https://orcid.org/0000-0001-6220-2626)
Lu Gao (ORCID: https://orcid.org/0000-0002-2206-5476)
Yanhua Hu (ORCID: https://orcid.org/0000-0002-8149-5636)
James G. Krueger (ORCID: https://orcid.org/0000-0002-3775-1778)
Subhashis Banerjee (ORCID: https://orcid.org/0009-0000-1365-5207)

Institutions

Bristol-Myers Squibb (United States) (US)
Bristol-Myers Squibb (Sweden) (SE)
Bristol-Myers Squibb (Belgium) (BE)
Rockefeller University (US)

Publication Details

Journal: Dermatology and Therapy
Published: 2024-09-16
DOI: https://doi.org/10.1007/s13555-024-01262-5
Citations: 5
Primary Topic: Psoriasis: Treatment and Pathogenesis
Type: article
Field-Weighted Citation Impact: 1.20

Funders

Bristol-Myers Squibb

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial

Ian M. Catlett, Lu Gao, Yanhua Hu, James G. Krueger et al.

Sep 16, 2024

5 citations

Dermatology and Therapy

Psoriasis: Treatment and Pathogenesis

1.20

article

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial

Ian M. Catlett, Lu Gao, Yanhua Hu, James G. Krueger, Subhashis Banerjee

September 16, 2024article en

5 citations

Abstract

No abstract available for this paper.

Dermatology and TherapyVol. 14(10)

Bristol-Myers Squibb (United States) (US), Bristol-Myers Squibb (Sweden) (SE), Bristol-Myers Squibb (Belgium) (BE), Rockefeller University (US)

Bristol-Myers Squibb

Good health and well-being

Openalex Percentile: Top 21%

Psoriasis: Treatment and Pathogenesis

1.20

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial — Ian M. Catlett, Lu Gao, et al. · Dermatology and Therapy (2024) | TGRS Research Map | TGRS